• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Aug. 1, 2016

View Archived Issues

Bench Press: BioWorld looks at translational medicine

Individuals who were able to make broadly neutralizing antibodies to HIV were also more prone to producing autoantibodies and had other metrics indicative of immune system dysfunction. Read More

In the clinic

Mallinckrodt plc, of Chesterfield, U.K., confirmed enrollment of the first patient in its phase III study of terlipressin (for injection) in subjects with hepatorenal syndrome (HRS) type 1, an acute, rare and life-threatening condition requiring hospitalization, with no currently approved therapy in the U.S. or Canada. Read More

Other news to note

Silvergate Pharmaceuticals Inc., of Denver, said the FDA approved Qbrelis, an oral solution of ACE inhibitor lisinopril, for the treatment of hypertension in adult patients and pediatric patients, 6 and older, as adjunct therapy for heart failure and as treatment of acute myocardial infarction in adults. Read More

Financings

Azurrx Biopharma Inc., of New York, sets terms for its IPO, hoping to raise $15 million from the sale of 2.14 million shares of common stock priced in the range of $6 and $8 each. The company is focused on therapies to treat gastrointestinal disorders. Read More

Unanswered questions linger on co-development of companion diagnostics

The FDA has published the long-awaited draft guidance for co-development of a therapeutic drug and a companion diagnostic, but the agency has scheduled an Aug. 18 webinar to address questions associated with the draft, a sign that the document leaves many questions unanswered. Read More

Whirled Seres: Tailspin after phase II strikeout to call foul on microbiome bids? Game not over

Seres Therapeutics Inc.'s stock-joltingly failed phase II study with SER-109 was not the first or only placebo-controlled microbiome trial against recurrent Clostridium difficile infection (CDI), and better (currently embargoed) news will roll out during scientific sessions this fall from Rebiotix Inc., with RBX2660, CEO Lee Jones told BioWorld Today. Read More

Jazz inks $181M blood cancer deal with Pfenex

Jazz Pharmaceuticals plc licensed global rights to several early stage blood cancer candidates from Pfenex Inc. in a deal that also included an option on an exclusive license for PF690, a biosimilar of Baxalta Inc.'s acute lymphoblastic leukemia (ALL) therapy, Oncaspar (pegaspargase), access to which could give Jazz wider reach in ALL. Read More

As big pharma reports earnings, is it a big deal or no deal?

Second-quarter earnings season wrapped up for big pharma with a sales miss by Sanofi SA as it sought to modify its tactical pursuit of Medivation Inc., which reports its financial results after the market close on Aug. 9. Read More

Proteins acting as RNA-binders may point to new heart disease cure

HONG KONG – A new study led by scientists at the Australian National University (ANU) has provided valuable insights into how the function of the human genome depends on RNA-binding proteins, an important discovery that could ultimately lead to the development of new treatments for heart disease. Read More

Pfizer: We'll conquer ALK challenge via second-gen plus broader NSCLC test

Figuring out which anaplastic lymphoma kinase inhibitor to use first in ALK-positive NSCLC, and handicapping the prospects for those coming through pipelines, has turned into a major challenge for oncologists, especially as resistance grows to New York-based Pfizer Inc.'s Xalkori (crizotinib), approved in August 2011 as a first-line treatment. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 4, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 4, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 3, 2025
  • KT-621: a first-in-class STAT6 degrader for Th2-driven diseases

    BioWorld Science
    STAT6 plays a central role in regulating Th2-driven immune responses. Recent studies have identified gain-of-function mutations in the STAT6 gene that are...
  • Woman holding neck

    Merus combo trounces Keytruda in head-and-neck phase II

    BioWorld
    Investor hopes rose sharply for Merus NV’s phase III trials – data should roll out next year – with bispecific antibody petosemtamab after mid-stage results...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe